JP2020527607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527607A5 JP2020527607A5 JP2020524697A JP2020524697A JP2020527607A5 JP 2020527607 A5 JP2020527607 A5 JP 2020527607A5 JP 2020524697 A JP2020524697 A JP 2020524697A JP 2020524697 A JP2020524697 A JP 2020524697A JP 2020527607 A5 JP2020527607 A5 JP 2020527607A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- therapeutically effective
- effective amount
- weeks
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 21
- 206010000496 acne Diseases 0.000 claims description 20
- 230000003902 lesion Effects 0.000 claims description 17
- 230000002757 inflammatory effect Effects 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- -1 methoxy (methyl) amino Chemical group 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- ZOGWILCBTHYRBE-UHFFFAOYSA-N OC1=C(C(C2C=C3C(C4=CC=CC(=C4CC3CC2C1)CN(C)OC)=O)=O)C(=O)N Chemical compound OC1=C(C(C2C=C3C(C4=CC=CC(=C4CC3CC2C1)CN(C)OC)=O)=O)C(=O)N ZOGWILCBTHYRBE-UHFFFAOYSA-N 0.000 description 1
- PQJQFLNBMSCUSH-SBAJWEJLSA-N chembl2364632 Chemical compound O=C1C2=C(O)[C@@](C(C(C(N)=O)=C(O)[C@H]3N(C)C)=O)(O)[C@H]3C[C@@H]2CC2=C1C(O)=CC=C2CN(C)OC PQJQFLNBMSCUSH-SBAJWEJLSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535572P | 2017-07-21 | 2017-07-21 | |
| US62/535,572 | 2017-07-21 | ||
| PCT/IB2018/000938 WO2019016609A1 (en) | 2017-07-21 | 2018-07-20 | TREATMENT OF NON-INFLAMMATORY LESIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020527607A JP2020527607A (ja) | 2020-09-10 |
| JP2020527607A5 true JP2020527607A5 (enExample) | 2021-02-25 |
Family
ID=63713912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524697A Pending JP2020527607A (ja) | 2017-07-21 | 2018-07-20 | 非炎症性病変の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200222432A1 (enExample) |
| EP (1) | EP3654988B1 (enExample) |
| JP (1) | JP2020527607A (enExample) |
| KR (1) | KR102662461B1 (enExample) |
| CN (1) | CN111343991A (enExample) |
| AU (1) | AU2018303807B2 (enExample) |
| BR (1) | BR112020000968A2 (enExample) |
| CA (1) | CA3070663A1 (enExample) |
| ES (1) | ES2962380T3 (enExample) |
| IL (1) | IL272124A (enExample) |
| MA (1) | MA49641A (enExample) |
| MX (1) | MX2020000816A (enExample) |
| WO (1) | WO2019016609A1 (enExample) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2990331A (en) | 1956-11-23 | 1961-06-27 | Pfizer & Co C | Stable solutions of salts of tetracyclines for parenteral administration |
| US2980584A (en) | 1957-10-29 | 1961-04-18 | Pfizer & Co C | Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3062717A (en) | 1958-12-11 | 1962-11-06 | Pfizer & Co C | Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3165531A (en) | 1962-03-08 | 1965-01-12 | Pfizer & Co C | 13-substituted-6-deoxytetracyclines and process utilizing the same |
| US3454697A (en) | 1965-06-08 | 1969-07-08 | American Cyanamid Co | Tetracycline antibiotic compositions for oral use |
| NL6607516A (enExample) | 1966-05-31 | 1967-12-01 | ||
| DE1767891C3 (de) | 1968-06-28 | 1980-10-30 | Pfizer | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
| US3957980A (en) | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
| DE2442829A1 (de) | 1974-09-06 | 1976-03-18 | Merck Patent Gmbh | Tetracyclische verbindungen und verfahren zu ihrer herstellung |
| US4018889A (en) | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
| US4126680A (en) | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
| KR100926326B1 (ko) * | 2001-04-05 | 2009-11-12 | 콜라제넥스 파마슈티칼스, 인크 | 여드름 치료 방법 |
| US7704959B2 (en) * | 2006-10-03 | 2010-04-27 | Dow Pharmaceutical Sciences | Azithromycin for the treatment of nodular acne |
| PT2109602E (pt) | 2006-12-21 | 2014-05-23 | Paratek Pharm Innc | Derivados de tetraciclina para o tratamento de infecções bacterianas, virais e parasitárias |
| SI2120963T1 (sl) * | 2006-12-21 | 2019-02-28 | Paratek Pharmaceuticals, Inc. | Substituirane spojine tetraciklina za zdravljenje vnetnih kožnih motenj |
| WO2009141406A1 (en) * | 2008-05-21 | 2009-11-26 | Galderma Research & Development | Maintenance therapy regimen for treating acne |
| BRPI0913326C1 (pt) * | 2008-06-05 | 2021-05-25 | Dow Pharmaceutical Sciences | formulação farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água |
| RU2012104572A (ru) * | 2009-07-30 | 2013-09-10 | Аллерган, Инк. | Комбинация дапсона с адапаленом |
| US20140121188A1 (en) * | 2009-10-02 | 2014-05-01 | Foamix Ltd. | Compositions for the improved treatment of acne and related disorders |
| WO2012155146A1 (en) | 2011-05-12 | 2012-11-15 | Paratek Pharmaceuticals, Inc. | Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same |
| IL225240A0 (en) * | 2012-03-15 | 2013-06-27 | Meir Eini | Use of tetracycline compounds for wound care and skin restoration |
| GB201615693D0 (en) * | 2016-09-15 | 2016-11-02 | Combinatorx Infection Ltd | Combinations |
-
2018
- 2018-07-20 WO PCT/IB2018/000938 patent/WO2019016609A1/en not_active Ceased
- 2018-07-20 US US16/632,121 patent/US20200222432A1/en not_active Abandoned
- 2018-07-20 MA MA049641A patent/MA49641A/fr unknown
- 2018-07-20 EP EP18779747.7A patent/EP3654988B1/en active Active
- 2018-07-20 CA CA3070663A patent/CA3070663A1/en active Pending
- 2018-07-20 CN CN201880048978.1A patent/CN111343991A/zh active Pending
- 2018-07-20 KR KR1020207003934A patent/KR102662461B1/ko active Active
- 2018-07-20 ES ES18779747T patent/ES2962380T3/es active Active
- 2018-07-20 AU AU2018303807A patent/AU2018303807B2/en active Active
- 2018-07-20 BR BR112020000968-7A patent/BR112020000968A2/pt not_active Application Discontinuation
- 2018-07-20 MX MX2020000816A patent/MX2020000816A/es unknown
- 2018-07-20 JP JP2020524697A patent/JP2020527607A/ja active Pending
-
2020
- 2020-01-19 IL IL272124A patent/IL272124A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5890780B2 (ja) | 中枢を介する悪心および嘔吐を治療するための組成物および方法 | |
| JP2014515373A5 (enExample) | ||
| JP2505944B2 (ja) | （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物 | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2015522630A5 (enExample) | ||
| JP2006506378A5 (enExample) | ||
| JPS6143112A (ja) | 精神性欲機能障害治療剤 | |
| ME02474B (me) | Terapijski režimi | |
| JP2021509395A5 (enExample) | ||
| JP2005508963A5 (enExample) | ||
| JP2019533660A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| CN113230411B (zh) | 一种阿利沙坦酯或其盐与钙离子通道拮抗剂的复方药物组合物 | |
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| JP2006528949A5 (enExample) | ||
| JP5386478B2 (ja) | パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| JP2020527607A5 (enExample) | ||
| JP2014511850A5 (enExample) | ||
| US20050227949A1 (en) | Compositions and methods for treatment of viral and bacterial infections | |
| JP2015524460A5 (enExample) | ||
| JP6420923B1 (ja) | 医薬 | |
| JP2006508993A5 (enExample) | ||
| JP2014530249A5 (enExample) | ||
| CN110279691A (zh) | 一种外科术后护理镇痛药物及其用途 |